Safinamide

BreastfeedingPediatric
  • TRADE NAME: Xadago (Newron)
  • INDICATIONS: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing 'off' episodes
  • CLASS: Monoamine oxidase B inhibitor
  • HALF-LIFE: 20–26 hours

FDA APPROVAL DATE: 03/21/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Cyclobenzaprine, Dextromethorphan, Dopaminergic antagonists, Imatinib, Irinotecan, Isoniazid, Lapatinib, Linezolid, Meperidine, Methadone, Methylphenidate, Metoclopramide, Mitoxantrone, Other MAO inhibitors, Propoxyphene, Rosuvastatin, Serotonergic drugs, St John's Wort, Sulfasalazine, Sympathomimetics, Topotecan, Tramadol, Tricyclic or tetracyclic antidepressants

PREGNANCY CATEGORY: C

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.


Page last updated 05/24/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top